Dan Strack
Contributor since: 2013
Intellia Makes History. Can It Deliver A Cure?
Intellia Expands Its In Vivo Advantage
Workhorse Group: A Glimmer Of Hope
Clean Energy Fuels: Huge Market Opportunity, Terrible Margins
MP Materials: Poised For Growth From Electrification And Clean Energy
ContraFect And Its Narrowed Phase 3 Approach
Intellia Therapeutics Is At A Pivotal Moment
Intellia Therapeutics: A Look Back At 2019 And Forward To 2020
Audentes Therapeutics: Key Program Updates
Audentes Therapeutics' Upcoming Catalysts
Intellia Therapeutics: An In Vivo Advantage
REGENXBIO: An Underappreciated Leader In Gene Editing
IMAX To Return To Profitability
Disney Is A Buy On Improving Free Cash Flow
IMAX May Surprise Investors
IMAX Has Near And Long-Term Growth Catalysts
Five Prime Therapeutics At An Attractive Entry Level
Wayfair Has No Path To Profitability
Stumbling Blocks Loom For Domino's
IBM Should Buy Palo Alto Networks
ContraFect: More Dilution In Store
Gilead And Intellia Therapeutics A Natural Fit
NewLink Genetics Unfairly Punished
Under Armour: Now A Long-Term Buy?
Intellia Therapeutics: Game-Changing Technology Trading At Steep Discount
Five Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb
2016 Investment Themes And Top 7 Picks
ContraFect Is A Speculative Buy On Positive News From Phase 1 Trials
Cummins: Where's The Bottom?
AT&T Is Once Again A Buy
Can Amazon Grow Into Its Valuation?
AMC Entertainment Is Ready To Bounce